Reviva Pharmaceuticals has been awarded a U.S. patent covering the use of its experimental therapy brilaroxazine in treating people with pulmonary fibrosis. The patent, No. 12053477, granted by the U.S. Patent and Trademark Office specifically covers the use of brilaroxazine in idiopathic pulmonary fibrosis (IPF), as well…
US patent covers brilaroxazine in treating IPF, like diseases
Looking at the person sitting nearby, I’ll often say, “So what are you in for?” While to me the question is slightly reminiscent of a conversation between two inmates, that’s not the case in this example. This conversation starter also works at a transplant clinic. I was diagnosed with…
Brainomix, a U.K.-based software company, has joined forces with Boehringer Ingelheim, a German pharmaceutical company, to accelerate the diagnosis of pulmonary fibrosis (PF) in the U.S. and improve treatment access for people with scarring of the lungs. As part of the collaboration, Brainomix’s artificial intelligence (AI)-powered tool, called Brainomix 360…
Living with a rare disease is expensive. While I agree with the cliches that “money can’t buy happiness” and “time is more valuable than money,” the limited financial aid available to patients stresses me out. When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in 2016, I wasn’t thinking…
A Newsweek article from a few weeks ago was headlined, “Washington, D.C., Endures Most Blistering Heat Wave in Nearly 100 Years.” As I write this, another article, this one from The Washington Post, just dropped, warning that “D.C. area begins fifth heat wave amid one of its…
Enrollment has been completed for a Phase 2a study that’s testing idiopathic pulmonary fibrosis (IPF) treatment BBT-877, an investigational therapy from Bridge Biotherapeutics. The Phase 2a trial (NCT05483907) is evaluating the safety, tolerability, and efficacy of BBT-877 in 120 adults with IPF, ages 40 and older, with or…
Having the support of a loved one is a crucial aspect of the journey with chronic illness. Not having that support can make one feel alone and vulnerable. Conversely, the presence of a supportive partner, family member, or friend can help a patient build the emotional strength that is needed…
Oxygen is necessary for sustaining human life. Most people find the concentration of oxygen in room air (about 21%) to be adequate. For patients with pulmonary fibrosis, this concentration is often inadequate, making supplemental oxygen a life-sustaining necessity. When I was diagnosed with idiopathic pulmonary fibrosis…
Enrollment is complete for a Phase 3 clinical trial testing Tyvaso (treprostinil) inhalation solution for idiopathic pulmonary fibrosis (IPF), United Therapeutics, the therapy’s developer, said. The TETON 2 study (NCT05255991) will evaluate the treatment’s safety and efficacy in 597 adults with IPF, 40 years and older,…
When I was discharged from the hospital following my bilateral lung transplant, it was the beginning of a new segment of my journey. I went into surgery on July 10, 2021, and was discharged on July 20. This was about three and a half years after my diagnosis…
